There is plenty of data confirming that hepatitis C virus (HCV) infection is a predisposing factor for a B-cell non-Hodgkin's lymphoma (B-NHL) outbreak, while relatively few reports have addressed the role of HCV in affecting B-NHL patients' outcome. HCV infection may influence the short-term outcome of B-NHL because of the emergence of severe hepatic toxicity (HT) during immunochemotherapy. Furthermore, the long term outcome of HCV-related liver disease and patients' quality of life will possibly be affected by Rituximab maintenance, multiple-lines of toxicity during chemotherapy and hematopoietic stem cell transplantation. In this review, data dealing with aggressive and low-grade B-NHL were separately analyzed. The few retrospective papers reporting on aggressive B-NHL patients showed that HCV infection is a risk factor for the outbreak of severe HT during treatment. This adverse event not infrequently leads to the reduction of treatment density and intensity. Existing papers report that low-grade B-NHL patients with HCV infection may have a more widespread disease, more frequent relapses or a lower ORR compared to HCV-negative patients. Notwithstanding that, there is no statistical evidence that the prognosis of HCV-positive patients is inferior to that of HCV-negative subjects. HCV-positive prospective studies and longer follow-up are necessary to ascertain if HCV-positive B-NHL patients have inferior outcomes and if there are long term sequels of immunochemotherapies on the progression of liver disease.

HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions / Cox, M. C.; ALOE SPIRITI, Maria Antonietta; Cavalieri, E.; Alma, E.; Gigante, E.; Begini, Paola; Rebecchini, C.; DELLE FAVE, Gianfranco; Marignani, M.. - In: WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY. - ISSN 1948-5204. - STAMPA. - 4:(2012), pp. 46-53. [10.4251/wjgo.v4.i3.46]

HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions.

ALOE SPIRITI, Maria Antonietta;BEGINI, PAOLA;DELLE FAVE, Gianfranco;
2012

Abstract

There is plenty of data confirming that hepatitis C virus (HCV) infection is a predisposing factor for a B-cell non-Hodgkin's lymphoma (B-NHL) outbreak, while relatively few reports have addressed the role of HCV in affecting B-NHL patients' outcome. HCV infection may influence the short-term outcome of B-NHL because of the emergence of severe hepatic toxicity (HT) during immunochemotherapy. Furthermore, the long term outcome of HCV-related liver disease and patients' quality of life will possibly be affected by Rituximab maintenance, multiple-lines of toxicity during chemotherapy and hematopoietic stem cell transplantation. In this review, data dealing with aggressive and low-grade B-NHL were separately analyzed. The few retrospective papers reporting on aggressive B-NHL patients showed that HCV infection is a risk factor for the outbreak of severe HT during treatment. This adverse event not infrequently leads to the reduction of treatment density and intensity. Existing papers report that low-grade B-NHL patients with HCV infection may have a more widespread disease, more frequent relapses or a lower ORR compared to HCV-negative patients. Notwithstanding that, there is no statistical evidence that the prognosis of HCV-positive patients is inferior to that of HCV-negative subjects. HCV-positive prospective studies and longer follow-up are necessary to ascertain if HCV-positive B-NHL patients have inferior outcomes and if there are long term sequels of immunochemotherapies on the progression of liver disease.
01 Pubblicazione su rivista::01a Articolo in rivista
HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions / Cox, M. C.; ALOE SPIRITI, Maria Antonietta; Cavalieri, E.; Alma, E.; Gigante, E.; Begini, Paola; Rebecchini, C.; DELLE FAVE, Gianfranco; Marignani, M.. - In: WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY. - ISSN 1948-5204. - STAMPA. - 4:(2012), pp. 46-53. [10.4251/wjgo.v4.i3.46]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/462206
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 5
social impact